NEXIGN
Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, and MegaFon, the pan-Russian operator of digital opportunities, have completed the project of unifying billing systems for all 8 MegaFon’s subsidiaries on a single BSS platform. The companies also migrated subscriber data to the new environment with no impact on customers.
The need to go beyond classical telecom services pushed MegaFon to transform the billing core and develop a unified billing system in order to facilitate digital transformation. Among the strategic goals of the project were the reduction of total cost of ownership (TCO) by 20–30% and acceleration of new product launches.
In the course of the project, 7 billing systems utilized in MegaFon were replaced with a single solution. The process was seamless for customers, and the specifics and working arrangements of individual organizations was taken into account during the migration of the B2X segment.
MegaFon achieved the following results:
- Unification of processes for all branch offices;
- Transition from a regional-based to a single shared operation service, which resulted in the increase of its efficiency;
- The product portfolio aligned within all branches of the operator while maintaining the flexibility of local pricing policy;
- Introduction of joint call centers with the same service KPIs and standardized routes for handling calls;
- Improved quality of customer service in the operator’s coverage area;
- Time to market (TTM) for various product categoriesreduced by 2-5 times.
“The collaboration with Nexign has proven to be efficient and successful. We pursued a number of goals traditional for large companies. Aside from optimizing TCO and shortening the time to market for new services, we aimed to improve the customer experience and, as a result, facilitate digital and business transformation. We managed to move all 8 subsidiaries to unified billing processes and switch to a single operation service, which minimized support costs and enabled us to develop an ecosystem for the seamless integration of external partners,” says Sergey Nikiforets, Director of Digital Services at MegaFon PJSC .
Besides the actual implementation of the unified billing system, a number of related projects were completed:
- The integration of the FastTrack methodology designed to automate the update implementation process. Consequently, the team responsible for it decided to spend no more than two weeks on minor changes to the system core — a process that used to last for about a year.
- Development of a microservice factory . Its goal was to accelerate the formation of a partner ecosystem. By using this tool, MegaFon has already launched more than 100 new business projects.
- The introduction of a product catalog that acts as a single point of development and modification of MegaFon’s products and services.
“The joint project with MegaFon is unique for the telecommunications market — both in terms of organized interaction and in terms of results achieved. The Nexign team carried out a comprehensive transformation of the operator’s systems, which enabled MegaFon to not only improve business efficiency and enter a new phase of development, but also to ensure customer loyalty while maintaining a high level of service in all regions. Whereas MegaFon will be able to upgrade the unified billing system to address short-term and long-term business challenges, Nexign’s scalable expertise will benefit telcos looking to develop digital services,” says Igor Gorkov, CEO of Nexign.
About Nexign
Nexign , a part of Intellectual Computer Systems Holding (ICS Holding) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering value-driven, high-performance product solutions since 1992. Headquartered in St. Petersburg, Nexign employs more than 1,800 people. The company has offices and subsidiaries through Russia, the Commonwealth of Independent States, the Middle East, Africa and LATAM.
For more information, please visit the website and follow the latest news from Nexign on Twitter , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005340/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom